Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of SRF388 in Patients With Advanced Solid Tumors

Miscellaneous

This is a Phase 1 / 1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Miscellaneous
I
Rini, Brian
NCT04374877
VICCMDP2083

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: